New coverage in cannabis pharma sector with over 1300% upside potential | Revive Therapeutics

Shares :


Introducing New Featured Stock Pick : Revive Therapeutics Ltd. | RVV

The Cannabis Stock is proud to begin coverage of one of the most undervalued companies in the promising cannabis-based biopharma sector Revive Therapeutics Ltd. | RVV.

The pharma cannabis market worldwide is huge and valued at more than $180 billion according to a report by Eight Capital.

Global Market valued at more than $180 billion

With a new management team recently, REVIVE THERAPEUTICS LTD | RVV has just provided updated news on their clinical development plan for Autoimmune liver diseases, IRI (prevention of ischemia and reperfusion injury from organ transplantation) and inflammatory skin diseases and disorders.

According to Michael Frank, Chief Executive Officer of Revive :

“Revive is leveraging its unique intellectual property portfolio and is focusing its efforts on building a pipeline of cannabinoid- based treatments for rare inflammatory diseases targeting multi-billion dollar markets,”

“We are focused on building a unique cannabinoid-based product pipeline that focuses on rare inflammatory diseases including autoimmune liver diseases, IRI and inflammatory skin diseases and disorders. In addition to expanding our product pipeline, we are focused on partnering our product programs with cannabinoid-focused pharmaceutical companies, which we are currently in discussions with for both our cannabinoid delivery system and rare inflammatory disease programs. ”

UPDATE | Revive Enters into Psychedelics Market | LOOK HERE

UPDATE | Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19| LOOK HERE

Revive Therapeutics Ltd Highlights

Revive Therapeutics Ltd owns several patents and FDA orphan drug designation as well as exclusive agreements including:

| 4 Exclusive licenses to patents in delivery system and liver disease

| 2 FDA orphan drug designation for CBD in treatment of AIH and prevention IRI from solid organ transplantation

| Exclusive Worldwide License Agreement with WARF (cannabinoid delivery technology)

|7 Strategic relationships

Undervalued VS Peers

The new management team intends to restore shareholder value and several major developments are coming which should bring the company’s values ​​closer to its peers.

Revive Therapeutics Ltd has a valuation of only around $3.5 million with only 72 million shares outstanding.

*Value at 2020-02-06

Revive Therapeutics Ltd VS cannabinoid-focused pharmaceutical

With the start of the clinical development plan for Autoimmune liver diseases and the prevention of IRI from organ transplantation, the company mentions that it is currently in discussions with cannabinoid-focused pharmaceutical companies which opens the door to several possible developments such as acquisitions or deals as already seen.

Pharma deals in liver diseases

| Allergan / Tobira: $ 1.7 Billions Acquisition
| Novartis / Conatus $ 650 Million License
| Gilead / Nimbus $ 1.2 Billions Acquisition

Pharma deals in skin diseases

| Purdue / Exicure $ 790 Million License
| Astra / Valeant $ 445 Million License
| Allergan / Vitae $ 639 Million Deal

Revive Therapeutics Ltd is currently trading on :

CSE market under the symbol RVV

OTC under the symbol RVVTF


To be informed of the next developments of Revive Therapeutics Ltd. Join our newsletter below and consult our Revive Therapeutics Ltd profil HERE

Revive Therapeutics Ltd. is a cannabis life sciences company focused on the research, development and commercialization of novel cannabinoid-based products. The Company’s novel cannabinoid delivery technology is being advanced to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory and liver diseases. For more information, visit

This article is written and published by The Cannabis Stock

Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies.

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Disclosure : Revive Therapeutics Ltd is a paid clients of The Cannabis Stock.

Click on a star to rate this article !

Average rating 3.8 / 5. Vote count: 9

No votes so far! Be the first to rate this post.

Shares :